Major adverse cardiovascular events in immune-mediated thrombotic thrombocytopenic purpura during clinical remission

Gelijkaardige items

• Major adverse cardiovascular events in immune-mediated thrombotic thrombocytopenic purpura during clinical remission
  door: Pasquale Agosti, et al.
  Gepubliceerd in: (2026-06-01)
• Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura
  door: Silvia Riva, et al.
  Gepubliceerd in: (2020-07-01)
• More on the pathogenesis of thrombotic thrombocytopenic purpura. Comment on “Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism” and on “The different faces of thrombotic thrombocytopenic purpura”
  door: Flora Peyvandi
  Gepubliceerd in: (2025-01-01)
• Acquired thrombotic thrombocytopenic purpura and HIV infection: a case report and review of the literature
  door: Silvio Rao, et al.
  Gepubliceerd in: (2026-01-01)
• Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients
  door: Marco Capecchi, et al.
  Gepubliceerd in: (2023-03-01)